Jim Cramer Says Stocks Like Johnson & Johnson "Simply Refuse to Quit"

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer commented on. Cramer showed an optimistic sentiment toward the stock, as he commented:

Lilly’s not alone. The irrepressible Johnson & Johnson, along with the effervescent Merck and Amgen, they simply refuse to quit. Why not? Even after the runs they’ve had this year alone, their stocks are not expensive versus the rest of the market. These are old-fashioned solid earners without the Tony Soprano overtones.

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases. Cramer discussed the company’s recent earnings during the episode aired on January 21, as he stated:

Alright, what do we make of these earnings from Johnson & Johnson? This morning, the pharma titan reported a healthy revenue beat and a very modest earnings beat with a strong full-year forecast, which is I care about. However, the stock was unchanged. Now, it was down much more than that intraday in response to the print in part because it was up more than 40% last year and had a run up another 5% year to date going in the quarter. One of the best pharmas there is.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.